关键词: text-indent: 0px, font: medium Simsun, white-space: normal, letter-spacing: normal, color: rgb(0, 0, 0), word-spacing: 0px, -webkit-text-stroke-width: 0px" id="x-370-anchor" name="x-370-anchor">

Abstract: Objective To evaluate the short-time effects and safety of brimonidine 0.2% and betaxolol 0.25% combined therapy in the treatment of patients with primary open-angle glaucoma (POAG) and ocular hypertension patients. Design Prospective case series. Participants POAG 32 cases (57 eyes), 14 cases (27 eyes) of ocular hypertension.Methods after a washing out phase, Brimonidine 0.2% combined Betaxolol 0.25% were administered to the participants twice daily. The Goldman intraocular pressure (IOP) and the side effects were observed before and after 2, 4, 8, 12 weeks the administration of the eye drops. The observing duration was 3 months. Main Outcome Measures IOP, adverse reaction. Results After two to twelve weeks of the combined madication, the average IOP decreased 5.71~7.38 mmHg, with an average decline of 21.94%~39.01% There was no significant difference between right and left eye (P>0.05), and between the genders (P>0.05). During follow-up, 3 patients exited the test because can’t tolerate eye irritation. 7 cases (8.33%) in eye secretions increase; 5 cases (5.95%) experienced eye hurt; the burning sensation in the eye in 10 cases (11.9%); 7 cases with bitter tast (8.33%); three cases (3.57%) appeared eyebrow with headache pain; the vision and anterior segment had no significant changes. Conclusion The short-time research results show that brimonidine 0.2% and betaxolol 0.25% combined therapy has bene?cial IOP-lowering effects and few side effects for the patients with POAG or ocular hypertension. 

Key words: text-indent: 0px, font: medium Simsun, white-space: normal, letter-spacing: normal, color: rgb(0,0,0), word-spacing: 0px, -webkit-text-stroke-width: 0px" id="x-370-anchor" name="x-370-anchor">